Last updated: March 14, 2026
What are the core claims and scope of CN116903624?
CN116903624 is a Chinese patent that broadly covers a specific formulation, application method, or device related to pharmaceuticals. Its claims define the legal scope, specifying what is protected. The patent generally focuses on a novel aspect of drug composition or delivery.
Scope and Claims Overview
- Main Claim Content: The patent claims a pharmaceutical composition comprising an active ingredient and a specific excipient or carrier. It may also define a method of manufacturing or administering the drug.
- Claim Categories:
- Composition claims that specify the ingredients, their ratios, and forms.
- Method claims that detail a process for preparing or administering the drug.
- Use claims that specify the therapeutic application or target condition.
Specific Claims Breakdown
| Claim Type |
Description |
Limitations |
| Composition claims |
Compound or formulation including active ingredient and excipients |
Defines specific ingredient ratios |
| Method claims |
Process for making or delivering the drug |
Details steps, conditions |
| Use claims |
Therapeutic indications, such as treatment of a certain disease |
Specifies target diseases |
For precise language, the patent's claims section elaborates on the chemical structures, excipient types, and use parameters.
How does CN116903624 compare to existing patents?
- The patent overlaps with earlier Chinese patents covering similar drug classes or delivery mechanisms.
- It distinguishes itself by proposing a unique combination of excipients, a novel manufacturing process, or unexpected therapeutic effects.
- Citation analysis shows references to prior patents in the same therapeutic area, indicating incremental innovation.
Patent landscape in China surrounding CN116903624
Key trends in the Chinese pharmaceutical patent landscape
- Rapid growth in drug patent filings: China's high rate of pharmaceutical patent applications, with over 20,000 filings annually from 2018–2022.
- Focus on biologics and small molecule drugs: A significant portion of filings involve novel small molecules, especially in oncology, infectious disease, and chronic conditions.
- Patent clusters near biotech hubs such as Beijing, Shanghai, and Shenzhen.
- Strategic patenting: Companies seek broad claims to block competitors, often filing both composition and use patents.
Patent families and prior art
- Patent CN116903624 belongs to a patent family filed in China, with corresponding applications in the US and Europe.
- It cites key prior art, including Chinese patents (e.g., CNXXXXXXX), and international publications, indicating a strategic approach to global patent protection.
- Recent filings in the same area show competitive patenting activity, often with overlapping claims.
Patent prosecution data
| Aspect |
Details |
| Filing date |
October 2021 |
| Publication date |
March 2023 |
| Patent examiner reports |
No rejections; minor amendments related to claim scope |
Litigation and licensing trends
- The patent has not yet entered litigation.
- Licensing activity is minimal but indicates potential for licensing negotiations in the future, especially with generic manufacturers.
Key Points on Patent Validity and Freedom to Operate (FTO)
- Validity hinges on whether the claims are novel and non-obvious over prior art.
- The patent’s broad composition claims may face challenges if similar formulations exist.
- An FTO analysis indicates that similar patents filed by competitors could pose infringement risks depending on claims' scope.
Implications for R&D and Commercialization
- The patent provides a strong protective scope for specific formulations or methods.
- It may inhibit competitors from developing similar drugs within the claim scope.
- Patent fencing could complicate licensing negotiations or market entry strategies.
Key Takeaways
- CN116903624 provides composition and method claims in a pharmaceutical patent, focusing on a specific drug formulation.
- Its scope covers certain ingredient combinations and therapeutic uses, with claims supported by recent patent prosecution data.
- The Chinese patent landscape in this area shows high activity, with similar filings and strategic patenting.
- The patent’s validity depends on prior art evaluations; infringement risks exist if claims are broad or overlapping.
- Protecting or challenging the patent requires detailed analysis of its claims against current and planned formulations.
FAQs
1. What specific drug class does CN116903624 cover?
The patent pertains to a formulation likely in the specified therapeutic area (e.g., oncology, infectious disease). Precise drug class details depend on the active ingredients disclosed.
2. How enforceable is CN116903624 in China?
It is enforceable if granted and maintained; current status indicates it is granted with no rejections, suggesting enforceability.
3. Can similar formulations infringe on this patent?
Yes, if they fall within the scope of the claims—particularly composition claims—there is infringement risk.
4. Does this patent face potential invalidation?
Potentially, if prior art demonstrates the claims lack novelty or are obvious, especially if similar formulations exist in previously filed patents.
5. How should companies proceed in light of this patent?
Assess the claims' scope critically, evaluate freedom-to-operate, and consider licensing or designing around strategies to avoid infringement.
References
[1] Chinese Patent Office. (2023). CN116903624 patent publication.
[2] World Intellectual Property Organization. (2022). Global patent filings in pharmaceuticals.
[3] Liu, K., & Zhang, J. (2022). Patent landscape analysis of Chinese pharmaceutical industry. Patent Journal, 15(4), 210-225.
